Related Experiment Video
Updated: Jun 30, 2026
06:57
The WinCF Model - An Inexpensive and Tractable Microcosm of a Mucus Plugged Bronchiole to Study the Microbiology of Lung Infections
Published on: May 8, 2017
Update on non-cystic fibrosis bronchiectasis
1Royal Brompton Hospital, Sydney Street, London, UK. d.bilton@rbht.nhs.uk
Current Opinion in Pulmonary Medicine
|September 25, 2008
Summary
Non-cystic fibrosis bronchiectasis requires systematic investigation to identify underlying causes like immunodeficiency. Understanding bacterial roles and treatment responses is crucial for effective management in adults and children.
Area of Science:
- Respiratory Medicine
- Clinical Immunology
Background:
- Growing awareness of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric respiratory clinics.
- Debate exists on the necessity of investigations to determine the underlying cause of NCFB.
- Increasing interest in the role of bacterial infections in NCFB disease progression.
Purpose of the Study:
- To review the current understanding and management of NCFB.
- To highlight the importance of identifying underlying causes, including immunodeficiency.
- To discuss the role of specific pathogens, such as nontuberculous mycobacteria and Pseudomonas aeruginosa, in NCFB.
Main Methods:
- Systematic review of recent literature on NCFB.
- Analysis of diagnostic approaches for NCFB.
- Evaluation of treatment strategies for NCFB.
Main Results:
- Post-infectious causes are less common in developed countries; immunodeficiency is increasingly recognized.
- Nontuberculous mycobacteria are implicated in causing and complicating NCFB.
- Conflicting evidence exists regarding Pseudomonas aeruginosa prognosis; NCFB patients may not respond to cystic fibrosis regimens.
Conclusions:
- NCFB can be systematically investigated to determine its cause.
- Developing targeted treatment strategies is essential for managing NCFB effectively.
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History